850 results match your criteria: "Luigi Hospital[Affiliation]"
J Thorac Oncol
November 2024
Department of Thoracic Oncology, LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
Introduction: RELAY, a global double-blind, placebo-controlled phase 3 study (NCT02411448) found statistically significant improvement in progression-free survival (primary end point) for ramucirumab (RAM) plus erlotinib (ERL) (RAM + ERL) in patients with untreated EGFR-mutated metastatic NSCLC (hazard ratio [HR] = 0.59, 95% confidence interval [CI]: 0.46-0.
View Article and Find Full Text PDFOncol Ther
November 2024
Department of Public Health, Federico II University of Naples, Naples, Italy.
Introduction: Personalized medicine has revolutionized the clinical management of patients with solid tumors. However, the large volumes of molecular data derived from next-generation sequencing (NGS) and the lack of harmonized bioinformatics pipelines drastically impact the clinical management of patients with solid tumors. A possible solution to streamline the molecular interpretation and reporting of NGS data would be to adopt automated data analysis software.
View Article and Find Full Text PDFEur J Cancer
December 2024
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Electronic address:
Lung Cancer
November 2024
Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, TO, Italy.
While recent randomized controlled trials (RCT) have suggested superior overall survival (OS) outcomes with segmentectomy over lobectomy, questions remain regarding the comparability of these surgical procedures for treating early-stage non-small cell lung cancer (NSCLC). This systematic review and meta-analysis aimed to synthetize existing evidence and to compare the survival outcomes observed for stage IA NSCLC following segmentectomy or lobectomy. 40 studies (38 observational, 2 RCTs) encompassing 103,926 patients were analyzed.
View Article and Find Full Text PDFJ Hosp Infect
October 2024
Department of Public Health and Pediatrics, University of Turin, Turin, Italy.
Eur Urol Focus
October 2024
Department of Urology, Rush University, Chicago, IL, USA. Electronic address:
Eur Urol
October 2024
Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland.
J Endocrinol Invest
October 2024
Department of Medicine DIMED, University of Padova, Padova, Italy.
Eur Urol Oncol
September 2024
The Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Lung Cancer
October 2024
Department of Oncology, Università degli Studi Di Torino - San Luigi Hospital Orbassano, Italy.
ESMO Open
September 2024
Department of Medicine and Surgery, University of Parma, Parma; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
J Exp Clin Cancer Res
August 2024
Department of Oncology, University of Torino, Torino, Italy.
Updates Surg
August 2024
Thoracic Surgery Division, Department of Oncology, S. Luigi Gonzaga Hospital, University of Torino, Regione Gonzole 10, Orbassano, 10043, Turin, Italy.
Thymus is considered a non-functional remnant in adults, but some evidence suggest that it may harbor residual activity. Lung cancer patients represent the ideal model to study thymic residual activity, as their thymus can be easily harvested during surgery. This study was designed to confirm the presence of residual thymic activity both in adult mice (step 1) and in humans (step 2).
View Article and Find Full Text PDFFront Nutr
July 2024
Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Jerusalem, Israel.
Eur Urol Open Sci
September 2024
Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
Background And Objective: The purpose-built SHURUI single-port (SP) robotic platform has recently been introduced for several procedures in urology, general surgery, and gynecology. However, comparative evidence on its performance in relation to earlier models such as the da Vinci SP is lacking. Our aim was to compare the step-by-step techniques and 1-yr outcomes for radical prostatectomy (RP) between the SHURUI SP and da Vinci SP robots.
View Article and Find Full Text PDFJ Exp Clin Cancer Res
August 2024
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
Background: In non-small cell lung cancer (NSCLC) the efficacy of chemo-immunotherapy is affected by the high expression of drug efflux transporters as ABCC1 and by the low expression of ABCA1, mediating the isopentenyl pyrophosphate (IPP)-dependent anti-tumor activation of Vγ9Vδ2 T-lymphocytes. In endothelial cells ABCA1 is a predicted target of the transcription factor EB (TFEB), but no data exists on the correlation between TFEB and ABC transporters involved in the chemo-immuno-resistance in NSCLC.
Methods: The impact of TFEB/ABCC1/ABCA1 expression on NSCLC patients' survival was analyzed in the TCGA-LUAD cohort and in a retrospective cohort of our institution.
Cancers (Basel)
May 2024
Department of Oncology, University of Turin, San Luigi Hospital, 10124 Orbassano, Italy.
For patients diagnosed with advanced HER2-altered non-small cell lung cancer (NSCLC), the current standard of care is represented by a platinum-pemetrexed-based chemotherapy, eventually in combination with immunotherapy. Different pan-HER tyrosine kinase inhibitors have been evaluated in limited phase II trials, yielding generally unsatisfactory outcomes, although certain genotypes demonstrated some clinical benefit. Conversely, antibody-drug conjugates (ADCs) targeting HER2, particularly trastuzumab-deruxtecan, have shown promising results against HER2-mutant disease, including a great intracranial activity in patients with brain metastasis.
View Article and Find Full Text PDFJ Neuroendocrinol
August 2024
Department of medical oncology, EURACAN and ENETS Center of Excellence, Hospices Civils de Lyon, Lyon, France.
Lung carcinoid tumours are neuroendocrine neoplasms originating from the bronchopulmonary tract's neuroendocrine cells, accounting for only 1%-3% of all lung cancers but 30% of all neuroendocrine tumours. The incidence of lung carcinoids, both typical and atypical, has been increasing over the years due to improved diagnostic methods and increased awareness among clinicians and pathologists. The most recent WHO classification includes a subgroup of lung carcinoids with atypical morphology and higher mitotic count and/or Ki67 labelling index.
View Article and Find Full Text PDFFront Nutr
April 2024
The Robert H. Smith Faculty of Agriculture, Food & Environment, The Hebrew University of Jerusalem, Rehovot, Israel.
The impact of food processing on drug absorption, metabolism, and subsequent pharmacological activity is a pressing yet insufficiently explored area of research. Overlooking food-processing-drug interactions can significantly disrupt optimal clinical patient management. The challenges extend beyond merely considering the type and timing of food ingestion as to drug uptake; the specific food processing methods applied play a pivotal role.
View Article and Find Full Text PDFJ Pers Med
April 2024
Department of Oncology, University of Turin, San Luigi Hospital, 10043 Orbassano, Italy.
Life (Basel)
March 2024
Division of Urology, Department of Surgery, Annunziata Hospital, 87100 Cosenza, Italy.
Partial nephrectomy (PN) is the primary surgical method for renal tumor treatment, typically involving clamping the renal artery during tumor removal, leading to warm ischemia and potential renal function impairment. Off-clamp approaches have been explored to mitigate organ damage, yet few results have emerged about the possible effects on hemoglobin loss. Most evidence comes from retrospective studies using propensity score matching, known to be sensitive to PS model misspecification.
View Article and Find Full Text PDFAntioxidants (Basel)
April 2024
Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, 10043 Orbassano, Italy.
Lung Cancer
May 2024
Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Turin, Italy. Electronic address:
Aims: To date, precision medicine has revolutionized the clinical management of Non-Small Cell Lung Cancer (NSCLC). International societies approved a rapidly improved mandatory testing biomarkers panel for the clinical stratification of NSCLC patients, but harmonized procedures are required to optimize the diagnostic workflow. In this context a knowledge-based database (Biomarkers ATLAS, https://biomarkersatlas.
View Article and Find Full Text PDFCancers (Basel)
March 2024
Department of Urology, Rush University Medical Center, Chicago, IL 60612, USA.
Background: Upper tract urothelial carcinoma (UTUC) is a rare disease with a potentially dismal prognosis. We systematically compared international guidelines on UTUC to analyze similitudes and differences among them.
Methods: We conducted a search on MEDLINE/PubMed for guidelines related to UTUC from 2010 to the present.
Cancers (Basel)
March 2024
Division of Urology, Department of Surgery, Annunziata Hospital, 87100 Cosenza, Italy.
The aim of "Precision Surgery" is to reduce the impact of surgeries on patients' global health. In this context, over the last years, the use of three-dimensional virtual models (3DVMs) of organs has allowed for intraoperative guidance, showing hidden anatomical targets, thus limiting healthy-tissue dissections and subsequent damage during an operation. In order to provide an automatic 3DVM overlapping in the surgical field, we developed and tested a new software, called "ikidney", based on convolutional neural networks (CNNs).
View Article and Find Full Text PDF